Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Dec 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how well cardiac MRI (a special type of imaging that looks at the heart) can help us understand heart function in people who have recovered from COVID-19. Researchers want to see if this imaging can help identify the reasons behind ongoing heart and lung symptoms that some people experience after their COVID-19 illness. By doing this, they hope to find ways to improve treatments for these symptoms.

To participate in the study, individuals must be between the ages of 65 and 74 and have been hospitalized or visited the emergency room due to COVID-19. They need to have tested positive for the virus and experienced at least one related symptom, like trouble breathing or coughing. Participants will undergo cardiac imaging and will be closely monitored for any heart or lung issues. It's important to note that people with certain medical conditions or those who cannot provide consent due to cognitive challenges may not be eligible. This study aims to help us better understand and treat the lingering effects of COVID-19 on the heart and lungs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Emergency room presentation and/or hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea/vomiting, myalgias, fever, syncope/presyncope.
• Exclusion criteria:
• • Contraindication to CMR (i.e. non-compatible pacemaker/defibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \<30 ml/min/1.73m2).
• • Inability to provide informed consent (e.g. cognitive impairment).
• • Unrelated condition (e.g. neoplasm) with life expectancy \<12 months prohibiting follow-up.
• • Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \< 30 ml/min/1.73m2) will undergo non-contrast MRI but will not be excluded from this study.
• • Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.